Harrow, Inc. (HROW): A Bull Case Theory [Yahoo! Finance]
Harrow Health, Inc. (HROW)
Last harrow health, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Harrow, Inc.'s share was trading at $47.69 as of February 16th. HROW's trailing and forward P/E were 9.64 and 44.25 respectively according to Yahoo Finance. Tyler Olson/Shutterstock.com Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. HROW delivered a strong Q3, reporting record revenue of $71.6M, up 45% YoY and 12% QoQ, with adjusted EBITDA of $22.7M (+158% YoY) and a 31.7% margin. Non-GAAP EPS of $0.35 exceeded expectations, reflecting stable operating expenses and increasing operating leverage. Gross margins remained robust at 75% GAAP and 81% non-GAAP. While 2025 revenue guidance was slightly lowered to $270–280M due to a one-time $4–6M decline in ImprimisRx revenue, management emphasized that the issue is resolved and underlying growth trends remain intact. Harrow's balance sheet is strong, with $74M cash, $50M in additional liquidity, and refinancing that reduces interest co
Show less
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow Health, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- Harrow (HROW) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- Harrow (HROW) had its price target lowered by Cantor Fitzgerald from $94.00 to $91.00. They now have an "overweight" rating on the stock.MarketBeat
- Harrow (HROW) had its price target raised by HC Wainwright from $69.00 to $70.00. They now have a "buy" rating on the stock.MarketBeat
- Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Harrow to Present at Leerink Partner’s 2026 Global Healthcare ConferenceGlobeNewswire
HROW
Earnings
- 3/2/26 - Miss
HROW
Sec Filings
- 3/5/26 - Form 4
- 3/3/26 - Form 4
- 3/2/26 - Form 10-K
- HROW's page on the SEC website